References
- Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344: 1373–7
- Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer. Results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 1283–90
- Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214–20
- Schröder FH, Van der Cruijsen-Koeter I, de Koning HJ, Vi AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806–12
- Recker F, Kwiatkowski M, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less. The Aarau experience. J Urol 2001; 166: 851–5
- Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239–46
- Häggarth L, Ekman P, Egevad L. A new core-biopsy instrument with an end-cut technique provides prostate biopsies with increased tissue yield. BJU Int 2002; 90: 51–5
- Schröder FH, Damhuis RA, Kirkels WJ, De Koning HJ, Kranse R, Nijs HG, et al. European randomized study of screening for prostate cancer—The Rotterdam pilot studies. Int J Cancer 1996; 65: 145–51
- Sur RL, Borboroglu PG, Roberts JL, Amling CL. A prospective randomized comparison of extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and morbidity. Prostate Cancer Prostatic Dis 2004; 7: 126–31
- Eskicorapci SY, Baydar DE, Akbala C, Sofikerim M, Giinay M, Ekici S, et al. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45: 444–9
- Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175: 1605–12
- Fink KG, Hutarew G, Pytel A, Schmeller NT. Prostate biopsy outcome using 29 mm cutting length. Urol Int 2005; 75: 9–12
- Farkas A, Schneider D, Perrotti M, Cummings K, Ward W. National trends in the epidemiology of prostate cancer. 1973–1994. Evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444–9
- Hellborg H, Adolfsson J. Incidens och prevalens av cancer i Stockholm-Gotland regionen 1998–2004 Available from:, , www.sll.se/oc.
- Van Cangh PJ, De Nayer P, De Vischer L, Sauvage P, Tombal B, Lorge F, et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostate hyperplasia (BPH) in the diagnostic grey zone of 1.8 to 10 ng/mL total PSA. Urology 1996; 48: 67–70
- Hammerer P, Graefen M, Henke RP, Haese A, Huland E, Huland H. Ratio free/total PSA (%f-PSA) in men with total PSA 0.5-3 ng/ml: improvement for prostate cancer detection?. Prostate Cancer Prostatic Dis 2000; 3(Suppl 1)19
- Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA, Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml. Relation to biopsy strategy. J Urol 2001; 165: 757–60
- Lujan M, Paez A, Miravalles E, Fernandez I, Llanesa L, Berenguer A. Prostate cancer detection is also relevant in low prostate specific antigen ranges. Eur Urol 2004; 45: 155–9
- Klein EA. What is ‘insignificant’ prostate carcinoma? [Editorial]. Cancer 2004; 101: 1923–5
- Klotz L. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. Eur Urol 2005; 47: 16–21